Skip to main content
    C

    Co-Diagnostics, Inc. Common Stock (CODX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.22
    -0.03 (-13.03%)

    Market Cap: $2.72M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Co-Diagnostics, Inc. Common Stock (CODX) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Co-Diagnostics, Inc. Common Stock (CODX) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Co-Diagnostics, Inc. Common Stock reported EPS of -$1.02, above the -$1.25 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    44%(14/32)
    Avg Surprise
    -22.06%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.28
    RangeN/A
    3 analysts
    Revenue Consensus
    $176.46K
    Range$169.54K - $181.65K
    3 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    CODX has an expected report date of Mar 29, 2027.

    CODX Earnings Call

    The latest CODX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 32 quarters below that had an estimate, CODX beat 14, missed 17 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $282881, up 94.6% from $145380 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.02-$1.25-$1.25 - -$1.25+18.80%BeatN/A11 up, 0 downNov 10, 2026$282881
    Jun 30, 2026-$1.46-$3.00-$3.00 - -$3.00+51.33%BeatN/A10 up, 1 downAug 13, 2026$166131
    Mar 31, 2026-$4.09-$3.75-$3.90 - -$3.60-9.07%MissN/A20 up, 1 downMay 14, 2026$145954
    Dec 31, 2025-$4.44-$3.90-$3.90 - -$3.30-13.70%MissN/A21 up, 0 downMar 31, 2026$263922
    Sep 30, 2025-$4.66-$5.70N/A+18.25%BeatN/A10 up, 1 downNov 13, 2025$145380
    Jun 30, 2025-$7.01-$7.50N/A+6.53%BeatN/A11 up, 0 downAug 14, 2025$162910
    Mar 31, 2025-$7.72-$9.90N/A+22.02%BeatN/A11 up, 0 downMay 8, 2025$50277
    Dec 31, 2024-$0.38-$0.34-$0.34 - -$0.34-11.12%MissN/A10 up, 1 downMar 27, 2025$149325
    Sep 30, 2024-$9.82-$9.90N/A+0.81%BeatN/A10 up, 0 downNov 7, 2024$641141
    Jun 30, 2024-$7.50-$10.20N/A+26.47%BeatN/A10 up, 0 downAug 8, 2024$2.66M
    Mar 31, 2024-$9.81-$6.30N/A-55.71%MissN/A10 up, 0 downMay 9, 2024$467854
    Dec 31, 2023-$0.50-$0.20-$0.20 - -$0.20-150.00%MissN/A10 up, 0 downMar 14, 2024$3.56M
    Sep 30, 2023-$6.54-$8.70N/A+24.83%BeatN/A10 up, 0 downNov 9, 2023$2.46M
    Jun 30, 2023-$9.50-$7.20N/A-31.94%MissN/A10 up, 0 downAug 10, 2023$197806
    Mar 31, 2023-$6.91-$7.20-$7.21 - -$6.31+4.03%Beat-190.4%20 up, 0 downMay 11, 2023$601957
    Dec 31, 2022-$0.68-$0.15-$0.15 - -$0.15-353.33%Miss-372.0%30 up, 0 downMar 16, 2023$1.40M
    Sep 30, 2022-$2.38-$1.00-$2.40 - $0.60-138.00%Miss-120.9%40 up, 0 downNov 10, 2022$5.09M
    Jun 30, 2022-$2.91$2.10$0.00 - $4.50-238.57%Miss-129.4%30 up, 0 downAug 11, 2022$5.02M
    Mar 31, 2022$7.64$5.10N/A+49.80%Beat-2.1%30 up, 0 downMay 12, 2022$22.70M
    Dec 31, 2021$0.25$0.12$0.08 - $0.15+108.33%Beat-44.4%3N/AMar 24, 2022$20.40M
    Sep 30, 2021$11.40$6.30$6.01 - $6.31+80.95%Beat-28.3%31 up, 0 downNov 11, 2021$30.10M
    Jun 30, 2021$9.90$6.60$6.31 - $6.91+50.00%Beat-23.3%3N/AAug 12, 2021$27.36M
    Mar 31, 2021$7.80$6.00N/A+30.00%BeatN/A2N/AMay 13, 2021$20.02M
    Dec 31, 2020$0.45$0.48$0.46 - $0.49-6.25%MissN/A3N/AMar 25, 2021$27.15M
    Sep 30, 2020$15.90$21.15$14.71 - $26.13-24.82%MissN/A3N/ANov 16, 2020$21.82M
    Jun 30, 2020$12.90$19.50$13.81 - $20.72-33.85%MissN/A3N/AAug 13, 2020$24.04M
    Mar 31, 2020-$1.50-$1.20-$2.40 - -$1.20-25.00%MissN/A3N/AMay 14, 2020$1.55M
    Dec 31, 2019-$0.09-$0.09-$0.10 - -$0.080.00%In lineN/A3N/AMar 30, 2020$108566
    Sep 30, 2019-$3.00-$2.25-$2.40 - -$2.10-33.33%MissN/A2N/ANov 13, 2019$41434
    Jun 30, 2019-$2.40-$1.65-$2.40 - -$0.90-45.45%MissN/A2N/AAug 14, 2019$61574
    Mar 31, 2019-$2.70-$2.40-$2.40 - -$2.40-12.50%MissN/A2N/AApr 2, 2019$3400
    Dec 31, 2018-$0.15-$0.13-$0.13 - -$0.13-15.38%MissN/A1N/ADec 31, 2018$10823
    Sep 30, 2018-$0.13N/AN/AN/AN/AN/AN/AN/ANov 14, 2018$9696
    Jun 30, 2018-$0.11N/AN/AN/AN/AN/AN/AN/AAug 10, 2018$9696
    Mar 31, 2018-$0.11N/AN/AN/AN/AN/AN/AN/AMay 14, 2018$9696
    Dec 31, 2017-$0.12N/AN/AN/AN/AN/AN/AN/AMar 28, 2018$2598
    Sep 30, 2017-$0.33N/AN/AN/AN/AN/AN/AN/ANov 14, 2017$2598
    Jun 30, 2017-$0.07N/AN/AN/AN/AN/AN/AN/AAug 25, 2017$2466
    Last 38 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$23.83, after -$27.51 the year before. It was -$0.52 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$23.83N/A
    Dec 31, 2024-$27.51N/A
    Dec 31, 2023-$23.45-1504.2%
    Dec 31, 2022$1.67-94.3%
    Dec 31, 2021$29.35+5.8%
    Dec 31, 2020$27.75N/A
    Dec 31, 2019-$8.19N/A
    Dec 31, 2018-$0.50N/A
    Dec 31, 2017-$0.52N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,100 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,1025
    2026Q1Mar 31, 20263,7025
    2025Q4Dec 31, 20253,8156
    2025Q3Sep 30, 20253,7796
    2025Q2Jun 30, 20253,2915
    2025Q1Mar 31, 20253,2305
    2024Q3Sep 30, 20243,0065
    2024Q2Jun 30, 20242,8615

    2026Q2 Earnings Call

    Opening remarks

    Andrew Benson Head of Investor Relations Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co-Diagnostics, we have Dwight H. Egan, Chief Executive Officer, and Brian L. Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results for the second quarter ended 06/30/2026. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analyst Q&A. Before we begin, we would like to inform listeners that certain statements made by Co-Diagnostics during this call are not historical facts and are forward-looking statements. In addition to diagnostic test developments and clinical evaluation timelines, this includes statements concerning regulatory review and clearance, commercialization plans and timing, international regulatory and manufacturing initiatives, financing and liquidity, and the capabilities and potential uses of the company's technology and data infrastructure. The company's Co-Dx PCR testing platform and related tests are subject to regulatory review, clearance, or authorization and are not currently for sale. Actual outcomes and results may differ materially from what is expressed or implied in any statement. Important factors which could cause actual results to differ materially from those in these forward-looking statements are described in the company's annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with the SEC, including under the heading Risk Factors, as well as in today's earnings release. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. In addition, the company may discuss certain non-GAAP financial measures during today's call. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release issued shortly before this call which contains reconciliations to the non-GAAP financial measures presented to their most comparable GAAP results. At this time, I would like to turn the call over to Co-Diagnostics' Chief Executive Officer, Dwight H. Egan. Dwight.

    Dwight H. Egan Chief Executive Officer Thank you everyone for joining us today and for your continued support of Co-Diagnostics. This past quarter marked another important step in our transition from platform development toward commercialization. We continued to advance the regulatory, clinical, commercial, and technology initiatives that support our long-term growth strategy. Over the past several years, we have invested in building a differentiated molecular diagnostics platform. Recently, those investments have translated into solid execution across our highest strategic priorities. The milestones we discussed today reflect continued execution against our long-term strategy.

    Frequently Asked Questions About CODX

    When is Co-Diagnostics, Inc. Common Stock's next earnings date?

    Co-Diagnostics, Inc. Common Stock's next earnings report is expected for Mar 29, 2027.

    Did CODX beat earnings estimates last quarter?

    Yes. Co-Diagnostics, Inc. Common Stock reported EPS of -$1.02 for the quarter ended Sep 30, 2026, above the -$1.25 estimate, a 18.80% surprise.

    What EPS do analysts expect from CODX next quarter?

    The consensus EPS estimate for Co-Diagnostics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.28 from 3 analysts.

    How often does CODX beat earnings estimates?

    Co-Diagnostics, Inc. Common Stock beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +10.38%.